Berry Genomics is a biotechnology company that develops high-throughput gene sequencing technology and works to translate it into clinical applications for human health.
PacBio supports Berry Genomics in securing China’s first regulatory approval for clinical long-read sequencing. NMPA Class III approval covers the PacBio Sequel II CNDx long-read sequencer and a thalassemia assay through the Berry partnership. PacBio describes the decision as the world’s first clearance for a clinical-grade long-read sequencer.
Nov 2025 · PacBioNews article
PacBio announces shipment of Vega systems to Berry Genomicsglobenewswire.com/news-release/2025/01/08/3006351/16261/en/pacbio-announces-shipment-of-vega-systems-to-berry-genomics-to-support-its-clinical-assay-development-for-asian-markets.html
PacBio ships Vega systems to Berry Genomics to support clinical assay development for markets in China and across Asia. The shipment builds on the companies’ longstanding partnership.
Berry Genomics and Prenetics establish a joint venture to enter China's consumer genetics market. The venture will focus on consumer genetics and direct-to-consumer testing in mainland China and involves CircleDNA.
Berry Genomics completes a backdoor reverse merger with Chengdu Tianxing at a valuation of 619 million. The listing is identified as Shenzhen Stock Exchange A shares under code 000710.
